Journal
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Volume 108, Issue 1, Pages 3-7Publisher
OXFORD UNIV PRESS
DOI: 10.1093/qjmed/hcu067
Keywords
-
Categories
Funding
- Wellcome Trust
- Medical Research Council (UK)
Ask authors/readers for more resources
Fibrosis, with resultant loss of organ function, is the endpoint of many diseases. Despite this, no effective anti-fibrotic therapies exist. The myofibroblast is the key cell driving fibrosis but its origins remain controversial. A growing body of work provides strong evidence that the pericyte, a perivascular cell present throughout the microvasculature, is a major myofibroblast precursor in multiple tissues. This review summarizes the principle experimental and clinical evidence underpinning this conclusion and outlines strategies for targeting pericyte transdifferentiation during fibrogenesis. Successful targeting of pro-fibrogenic pericytes has the potential to halt or even reverse fibrosis and thus reduce the enormous worldwide healthcare burden that currently exists as a result of fibrotic disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available